Johnson & Johnson (NYSE:JNJ) is one of the pharmaceutical companies that have been working on a vaccine for the coronavirus and it recently announced the commencement of phase 3 clinical trials.
The announcement by J&J adds to the number of pharmaceutical companies that have been making significant progress with their COVID-19 vaccine pursuits. Some of the other companies include Pfizer Inc. (NYSE: PFE), AstraZeneca plc (NYSE: AZN), and Moderna Inc (NASDAQ: MRNA). The recent announcement from the company revealed the launch of the phase 3 trial which will feature 60,000 subjects that will volunteer for the trial.
The clinical trial will take place in multiple countries and the potential vaccine has a trick up its sleeve
The subjects to participate in the phase 3 clinical trials will be enrolled in the U.S and numerous other countries that have a high number of people infected by the coronavirus. Most of the pipeline vaccines for the coronavirus require coronavirus patients to take multiple doses. J&J’s developmental COVID-19 vaccine is different because it requires the patient to take a single dose and this might make a more appealing option compared to what the competition has to offer.
If the clinical trials yield favorable results, it means patients will have an efficient option that only requires a single dose, which means that it will also be potentially more affordable. The fact that it is entering the phase 3 stage is also great news in terms of the treatment’s development. It means that so far the treatment has so far demonstrated notable capacity to combat the virus, otherwise the development would not have gotten this far.
"The [Johnson & Johnson] candidate has so far shown promise in early-stage testing and may be especially useful in controlling the pandemic if shown to be protective after a single dose," stated Anthony Fauci, the lead infectious disease expert for the U.S government.
As far as the timeline is concerned, J&J is optimistic that the findings from the phase 3 clinical trial will be favorable. If that will be the case, it plans to use the data from the clinical trial to file for emergency use authorization early next year.